Advanced search

Loading...

Advanced search    
Sort by: ▼ relevance publication date title journal

Search: authors:"Stella Karantzoulis"

4 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Using qualitative interviews to identify patient-reported clinical trial endpoints and analyses that are the most meaningful to patients with advanced breast cancer

, Gaia Schiavon. Formal analysis: Emuella Flood, Stella Karantzoulis, Julie Bailey, Solène Bayet, Arthur Elghouayel. 16 / 19 Investigation: Anna Krasnow, Stella Karantzoulis, Julie Bailey, Solène Bayet ... , Arthur Elghouayel. Methodology: Emuella Flood, Anna Krasnow, Cecilia Orbegoso, Stella Karantzoulis, Julie Bailey, Solène Bayet, Gaia Schiavon. Project administration: Anna Krasnow, Julie Bailey, Solène

Update on Dementia with Lewy Bodies

Stella Karantzoulis 0 James E. Galvin 0 0 J. E. Galvin Comprehensive Center on Brain Aging and Departments of Neurology and Psychiatry, New York University Langone Medical Center , New York, NY, USA ... for the Lewy Body Composite Risk Score. Compliance with Ethics Guidelines Conflict of Interest Stella Karantzoulis and James E. Galvin declare that they have no conflict of interest. Human and Animal

Rivastigmine in moderately severe-to-severe Alzheimer’s disease: Severe Impairment Battery factor analysis

The Severe Impairment Battery (SIB) is validated for assessing cognition in patients with severe dementia. The current analysis aimed to further investigate the cognitive efficacy of rivastigmine capsules, as assessed by SIB factor scores, in patients with moderately severe-to-severe Alzheimer’s disease (AD). This was a retrospective analysis of a 26-week, multicenter, randomized...

Rivastigmine in moderately severe-to-severe Alzheimer’s disease: Severe Impairment Battery factor analysis

Introduction The Severe Impairment Battery (SIB) is validated for assessing cognition in patients with severe dementia. The current analysis aimed to further investigate the cognitive efficacy of rivastigmine capsules, as assessed by SIB factor scores, in patients with moderately severe-to-severe Alzheimer’s disease (AD). Methods This was a retrospective analysis of a 26-week...